5 unknown, 4 completed, 3 recruiting. 12 Phase 1, 9 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Unknown 5, Completed 4, Recruiting 3 |
| Phase 2 | 9 | Unknown 4, Recruiting 3, Completed 2 |
Follow Treatment: new trials by email Literature Review of Treatment trials Research Report on Treatment
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML Ivosidenib, Venetoclax, Azacitidine - AML, IDH1 Mutation | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 23 | 2025-10-17 | 2026-05-13 |
| A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia nicotinamide adenine dinucleotid/nicotinamide mononucleotide - Immune Thrombocytopenia, Treatment | Phase 1 / Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 20 | 2025-01-15 | 2025-08-05 |
| First in Human Study of TLC-ART 101 (ACTU 2001) TLC-ART - Human Immunodeficiency Virus, Treatment | Phase 1 | Completed | University of Washington | 12 | 2023-04-01 | 2026-08-21 |
| Modulating Exercise Dosage to Improve Concussion Recovery High Dose Exercise - Concussion, Brain, Treatment | Phase 1 / Phase 2 | Recruiting | University of Colorado, Denver | 178 | 2022-08-05 | 2026-08-31 |
| Mitoxantrone Hydrochloride Liposomes in Combination With GDP in Relapsed/Refractory PTCL liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin - Treatment, Peripheral T-cell Lymphoma | Phase 1 / Phase 2 | Unknown | Peking Union Medical College Hospital | 60 | 2022-05-01 | 2022-07-01 |
| Ezrin Peptide (HEP-1) for Treatment of Coronavirus Disease (COVID-19) Infection Human Ezrin Peptide 1 (HEP1), Placebo - Covid19, Treatment | Phase 1 | Unknown | Shahid Beheshti University of Medical Sciences | 20 | 2020-12-20 | 2020-11-13 |
| Assessing an Oral EGFR Inhibitor,YK-209A in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR YK-029A - Treatment, Treatment Side Effects | Phase 1 / Phase 2 | Unknown | Suzhou Puhe Pharmaceutical Technology Co., LTD | 160 | 2018-03-30 | 2023-03-17 |
| PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia rituximab /Dexamethasone/cyclophosphamide, Velcade/Dexamethasone/cyclophosphamide - Treatment | Phase 1 / Phase 2 | Unknown | The First Affiliated Hospital of Soochow University | 40 | 2016-10-01 | 2016-11-23 |
| The Role of Mind Body Therapy in Geriatric Rehabilitation mind-body intervention - Elderly, Treatment | Phase 1 / Phase 2 | Unknown | Tel-Aviv Sourasky Medical Center | 2010-01-01 | 2010-02-05 | |
| Clinical Evaluation of PoreSkin PoreSkin - Treatment | Phase 1 | Completed | Chulalongkorn University | 11 | 2009-09-01 | 2015-07-01 |
| Assisting Children With Prenatal Alcohol Exposure in Developing Peer Friendships Parent assisted social skills training - Treatment, Control | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 100 | 2001-10-01 | 2005-11-08 |
| Intervening With Children/Adolescents With FAS/ARND Positive Behavior Support - Treatment, Control | Phase 1 / Phase 2 | Completed | Centers for Disease Control and Prevention | 52 | 2001-10-01 | 2005-09-14 |
Acquired Immunodeficiency Syndrome (1) · Anxiety Disorders (1) · Brain Concussion (1) · Burns (1) · COVID-19 (1) · Coronavirus Infections (1) · Depression (1) · Inflammation (1) · Lymphoma, T-Cell, Peripheral (1) · Purpura, Thrombocytopenic, Idiopathic (1)
Immune System Diseases (3) · Hemic and Lymphatic Diseases (2) · Infections (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · RNA Virus Infections (2) · Virus Diseases (2) · Wounds and Injuries (2) · Autoimmune Diseases (1) · Behavior (1) · Behavioral Symptoms (1) · Blood Coagulation Disorders (1) · Blood Platelet Disorders (1) · Blood-Borne Infections (1) · Brain Diseases (1)
Dexamethasone (2) · Azacitidine (1) · Bortezomib (1) · Cisplatin (1) · Cyclophosphamide (1) · Exercise (1) · Gemcitabine (1) · NAD (1) · Nicotinamide Mononucleotide (1) · Rituximab (1) · ivosidenib (1) · venetoclax (1)
Centers for Disease Control and Prevention (2) · Institute of Hematology & Blood Diseases Hospital, China (2) · Chulalongkorn University (1) · Peking Union Medical College Hospital (1) · Shahid Beheshti University of Medical Sciences (1) · Suzhou Puhe Pharmaceutical Technology Co., LTD (1) · Tel-Aviv Sourasky Medical Center (1) · The First Affiliated Hospital of Soochow University (1) · University of Colorado, Denver (1) · University of Washington (1)
China (5) · United States (4) · Iran (1)
David R Howell, PhD (1) · Hui Wei, MD (1) · Hui Zhao, Doctor (1) · Lei Zhang, MD (1) · Mary O'Connor, PhD (1) · Rachel A Bender Ignacio, MD MPH (1) · Susan Astley, PhD (1)
PMID 37776953, PMID 39760650, PMID 40297050, PMID 40887012, PMID 40990413, PMID 41019467, PMID 41593831, PMID 41622533, PMID 41956449, PMID 42056497, PMID 42245142, PMID 42284615
R01HD108133 (1), U01AI148055 (1)